STOCK TITAN
  1. Home
  2. News
  3. FWBI

First Wave BioPharma Inc - FWBI STOCK NEWS

Welcome to our dedicated news page for First Wave BioPharma (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect First Wave BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of First Wave BioPharma's position in the market.

News
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
Rhea-AI Summary
First Wave BioPharma announced the publication of research on the impact of a gluten-containing diet on serologic status in celiac disease in the peer-reviewed scientific journal Nutrients. The research focuses on the findings from Phase 2 clinical trials of latiglutenase, a targeted oral biotherapeutic for celiac disease. The study discusses the return to seropositivity in patients resuming gluten for diagnostic purposes and the correlation between tTG-IgA assays. The research highlights the potential of latiglutenase to be safe, well-tolerated, and effective in breaking down gluten proteins implicated in celiac disease symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
none
-
News
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
Rhea-AI Summary
First Wave BioPharma CEO James Sapirstein is set to present at the Planet MicroCap Showcase, providing insights into the company's business and clinical development strategy. The event will take place on May 1, 2024, at the Paris Hotel & Casino in Las Vegas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
conferences
-
News
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
Rhea-AI Summary
First Wave BioPharma CEO James Sapirstein is set to participate in the 2024 Longwood Healthcare Leaders Conference, where the company will present its business and clinical development strategy to investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences
News
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Rhea-AI Summary
First Wave BioPharma announces poster presentations at DDW 2024 on new diagnostic methods for Celiac Disease, highlighting VCIEL scale and serologic changes to gluten. The presentations aim to enhance accuracy in measuring small intestinal mucosal health and improve understanding and treatment of the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
News
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
Rhea-AI Summary
First Wave BioPharma, Inc. announces the acquisition of ImmunogenX, focusing on advancing a GI pipeline with a potentially first-in-class oral biotherapeutic for celiac disease. The company plans to license the commercial rights to a global pharmaceutical company, secure financing, and initiate Phase 3 trials in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.76%
Tags
clinical trial
-
News
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
Rhea-AI Summary
First Wave BioPharma, Inc. announces CEO's participation in fireside chat at the 36th Annual Roth Conference. The event will focus on the company's business and clinical development strategy, recent achievements, and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.1%
Tags
conferences
News
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
Rhea-AI Summary
First Wave BioPharma, Inc. announces a registered direct offering and concurrent private placement to raise approximately $4.0 million for working capital and general corporate purposes. The Company will sell 525,625 shares of common stock at $7.61 per share, with warrants to purchase additional shares at $7.48 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.92%
Tags
offering
-
News
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
Rhea-AI Summary
First Wave BioPharma, Inc. announced that its Chairman and CEO will present at the BIO CEO & Investor Conference to discuss the company's business strategy and recent achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
conferences
-
News
First Wave BioPharma to Present at the DealFlow MicroCap Conference
Rhea-AI Summary
First Wave BioPharma, Inc. (FWBI) will present at the DealFlow MicroCap Conference to showcase its business and clinical development strategy for gastrointestinal diseases. The event will take place from January 30 to February 1, 2024, at the Caesars Atlantic City Hotel & Casino. The company's management team will conduct one-on-one meetings with registered investors to discuss recent corporate achievements and anticipated milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences
News
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
Rhea-AI Summary
First Wave BioPharma, Inc. (FWBI) is set to present at the Sequire Investor Summit 2024, showcasing their business and clinical development strategy for gastrointestinal diseases. The event is scheduled for January 23-25, 2024, in San Juan, Puerto Rico, with Chairman and CEO James Sapirstein leading the presentation on January 24. The company aims to engage with investors and highlight recent corporate achievements and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
Stock FWBI logo
First Wave BioPharma Inc

Nasdaq:FWBI

FWBI Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

FWBI Stock Data

6.72M
1.91M
6.76%
4.07%
2.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Brooklyn

About FWBI

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.